RUNX1 and acute myeloid leukemia: These findings suggest that while HSCT can mitigate the adverse impact of KIT mutations, it does not fully overcome the influence of immunophenotypic differences among LSC populations on clinical outcomes in RUNX1–RUNX1T1 AML.